FAILED TRIAL: Ph 2b SURVIVE Trial of SurVaxM in Newly Diagnosed GBM didn’t meet primary endpoint of OS improvement

Robert Fenstermaker, MD, co-principal investigator of the SURVIVE trial, Chair Emeritus of Neurosurgery at Roswell Park and Chief Medical Officer and Co-founder of MimiVax, added, “For patients 65 and under, this is one of the strongest signals we have seen in newly diagnosed glioblastoma in a long time. We designed the trial to provide a good comparison to our earlier Phase 2a study, while adding a placebo arm to account for improvements in standard of care that may have occurred over time. In a disease where progress has often been measured in weeks, results like these can be enormously meaningful.”

Share:

More News

Taiho Oncology, Inc. completed a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20

“This collaboration reflects our conviction that atebimetinib has the potential to become an essential backbone therapy in a broad range of combinations across MAPK-driven cancers,” said Ben Zeskind, Immuneering CEO and co-founder. “Atebimetinib’s unique tolerability profile and broad activity make it well suited to combine with a wide range of

“These final updated results provide continued evidence of the potential for γδ T cell therapies to drive activity and improve outcomes for patients,” said William Ho, CEO and co-founder of IN8bio. “The clinical outcomes and observed activity are supported by our correlative analysis, including histopathology, demonstrating the expansion and persistence

“Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and Fast Track designation reflects the potential of onvansertib to address this serious unmet need,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Our randomized Phase 2 data give us confidence that onvansertib